GlassScriptPhysician profile
Frank M Moro
NPI 1770550766
$10,354.58
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,522 · 2020: $2,575 · 2021: $3,400 · 2022: $2,343 · 2023: $375 · 2024: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $4,372.71 | 2020-2022 | |
| Novo Nordisk INC | $990.43 | 2019-2023 | Wegovy |
| Glaxosmithkline, LLC. | $790.53 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $776.22 | 2019-2022 | |
| Amarin Pharma, INC. | $492.38 | 2019-2021 | |
| Pfizer INC. | $366.44 | 2019-2022 | |
| Abbvie INC. | $321.29 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $294.08 | 2019-2022 | |
| Astellas Pharma US INC | $267.63 | 2019-2023 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $213.33 | 2019-2022 | |
| Allergan, INC. | $164.33 | 2020 | |
| Amgen INC. | $140.02 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $122.53 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $120.60 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.15 | 2019-2023 | Trintellix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105.49 | 2019-2022 | |
| Lilly USA, LLC | $96.59 | 2020-2023 | Mounjaro |
| Regeneron Healthcare Solutions, INC. | $95.43 | 2019 | |
| Eisai INC. | $94.08 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.50 | 2019-2022 | |
| Abbott Laboratories | $57.83 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $46.06 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.61 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $37.36 | 2021 | |
| Shield Therapeutics INC | $32.19 | 2023 | Accrufer |
| Mylan Specialty L.P. | $26.91 | 2019 | |
| Exact Sciences Corporation | $23.95 | 2023 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $17.94 | 2019 | |
| Nestle Healthcare Nutrition INC. | $17.38 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $15.91 | 2022 | |
| Merck Sharp & Dohme LLC | $14.37 | 2019 | |
| Boston Scientific Corporation | $13.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Moro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.